212 related articles for article (PubMed ID: 12779014)
1. Pretreatment with interleukin-2 modulates perioperative immunodysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Klatte T; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
Folia Biol (Praha); 2003; 49(2):63-8. PubMed ID: 12779014
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment with interleukin-2 modulates peri-operative immuno-dysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Schierbaum KF; Röhl FW; Ansorge S; Allhoff EP
Eur Urol; 2002 Apr; 41(4):458-67; discussion 467-8. PubMed ID: 12074819
[TBL] [Abstract][Full Text] [Related]
3. Complex perioperative immuno-dysfunction in patients with renal cell carcinoma.
Böhm M; Ittenson A; Philipp C; Röhl FW; Ansorge S; Allhoff EP
J Urol; 2001 Sep; 166(3):831-6. PubMed ID: 11490228
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment with interferon-alpha2a modulates perioperative immunodysfunction in patients with renal cell carcinoma.
Klatte T; Ittenson A; Röhl FW; Ecke M; Allhoff EP; Böhm M
Onkologie; 2008 Feb; 31(1-2):28-34. PubMed ID: 18268396
[TBL] [Abstract][Full Text] [Related]
5. Soluble immunological parameters and early prognosis of renal cell cancer patients.
Kallio JP; Tammela TL; Marttinen AT; Kellokumpu-Lehtinen PL
J Exp Clin Cancer Res; 2001 Dec; 20(4):523-8. PubMed ID: 11876546
[TBL] [Abstract][Full Text] [Related]
6. Relation of prenephrectomy CD profiles and serum cytokines to the disease outcome and response to IFN-alpha/IL-2 therapy in renal cell carcinoma patients.
Lauerová L; Dusek L; Spurny V; Simicková M; Rovny A; Rejthar A; Kocák I; Kovarík J
Oncol Rep; 2001; 8(3):685-92. PubMed ID: 11295103
[TBL] [Abstract][Full Text] [Related]
7. Functional and immunophenotypic modifications induced by interleukin-2 did not predict response to therapy in patients with renal cell carcinoma.
Favrot MC; Combaret V; Negrier S; Philip I; Thiesse P; Freydel C; Bijmann JT; Franks CR; Mercatello A; Philip T
J Biol Response Mod; 1990 Apr; 9(2):167-77. PubMed ID: 1971303
[TBL] [Abstract][Full Text] [Related]
8. Perioperative immunomodulation with interleukin-2 in patients with renal cell carcinoma: results of a controlled phase II trial.
Klatte T; Ittenson A; Röhl FW; Ecke M; Allhoff EP; Böhm M
Br J Cancer; 2006 Nov; 95(9):1167-73. PubMed ID: 17031403
[TBL] [Abstract][Full Text] [Related]
9. Hyporesponsiveness of T cell subsets after cardiac surgery: a product of altered cell function or merely a result of absolute cell count changes in peripheral blood?
Franke A; Lante W; Kurig E; Zöller LG; Weinhold C; Markewitz A
Eur J Cardiothorac Surg; 2006 Jul; 30(1):64-71. PubMed ID: 16730447
[TBL] [Abstract][Full Text] [Related]
10. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver.
Zaloudik J; Lauerova L; Janakova L; Talac R; Simickova M; Nekulova M; Mikulikova I; Kovarik J; Sheard M
Hepatogastroenterology; 1999; 46(25):220-7. PubMed ID: 10228796
[TBL] [Abstract][Full Text] [Related]
11. Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.
Rutkowski P; Kamińska J; Kowalska M; Ruka W; Steffen J
J Surg Oncol; 2003 Nov; 84(3):151-9. PubMed ID: 14598359
[TBL] [Abstract][Full Text] [Related]
12. Prospective comparison of the immunological and stress response following laparoscopic and open surgery for localized renal cell carcinoma.
Landman J; Olweny E; Sundaram CP; Chen C; Rehman J; Lee DI; Shalhav A; Portis A; McDougall EM; Clayman RV
J Urol; 2004 Apr; 171(4):1456-60. PubMed ID: 15017197
[TBL] [Abstract][Full Text] [Related]
13. Expanding the indications for surgery and adjuvant interleukin-2-based immunotherapy in patients with advanced renal cell carcinoma.
Belldegrun A; Shvarts O; Figlin RA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S88-92. PubMed ID: 10685666
[TBL] [Abstract][Full Text] [Related]
14. Infiltration of activated dendritic cells and T cells in renal cell carcinoma following combined cytokine immunotherapy.
Verra N; de Jong D; Bex A; Batchelor D; Dellemijn T; Sein J; Nooijen W; Meinhardt W; Horenblas S; de Gast G; Vyth-Dreese F
Eur Urol; 2005 Sep; 48(3):527-33. PubMed ID: 16115526
[TBL] [Abstract][Full Text] [Related]
15. [Cytokines and soluble cytokine receptors in the perioperative period].
Maruna P; Gürlich R; Frasko R; Chachkhiani I; Marunová M; Owen K; Pesková M
Sb Lek; 2002; 103(2):273-82. PubMed ID: 12688152
[TBL] [Abstract][Full Text] [Related]
16. Differential early posttransplant cytokine responses in living and cadaver donor renal allografts.
Sadeghi M; Daniel V; Weimer R; Wiesel M; Hergesell O; Opelz G
Transplantation; 2003 Apr; 75(8):1351-5. PubMed ID: 12717229
[TBL] [Abstract][Full Text] [Related]
17. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
Lauerová L; Dusek L; Simícková M; Rovný F; Spurný V; Rovný A; Slampa P; Zaloudík J; Rejthar A; Wotke J; Kovarík J
Neoplasma; 1999; 46(3):141-9. PubMed ID: 10613588
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2).
Abdel-Wahab M; El-Shennawy F; Agha S; Ragab E; Fathi O; Sultan A; Elghawalby N; Ezzat F
Hepatogastroenterology; 1999 May; 46 Suppl 1():1293-6. PubMed ID: 10429977
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of CD3/CD28-activated T cells (Xcellerated T cells) and interleukin-2 in patients with metastatic renal cell carcinoma.
Thompson JA; Figlin RA; Sifri-Steele C; Berenson RJ; Frohlich MW
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3562-70. PubMed ID: 14506142
[TBL] [Abstract][Full Text] [Related]
20. [Perioperative immune modulation in renal cell carcinoma--review of the current situation].
Böhm M; Klatte T; Allhoff EP
Aktuelle Urol; 2003 Sep; 34(5):319-27. PubMed ID: 14566659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
